UBS Group
PHAR

UBS Group’s Pharming Group PHAR Stock Holding History

UBS Group’s Portfolio PHAR Stock Details PHAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542 Buy
+39
New +$565 ﹤0.01% 9807
2026
Q1 		– Sell
-1
Closed -$18 – 11003
2025
Q4 		$18 Buy
+1
New +$16 ﹤0.01% 10360
2025
Q1 		– Sell
-10
Closed -$101 – 10594
2024
Q4 		$101 Buy
+10
New +$85 ﹤0.01% 9650
2024
Q3 		– Sell
-789
Closed -$6.59K – 9925
2024
Q2 		$6.59K Buy
789
+737
+1,417% +$6.94K ﹤0.01% 7906
2024
Q1 		$546 Buy
+52
New +$615 ﹤0.01% 8486
2023
Q2 		– Sell
-881
Closed -$11.9K – 9462
2023
Q1 		$11.9K Sell
881
-370
-30% -$4.67K ﹤0.01% 7468
2022
Q4 		$13.8K Sell
1,251
-283
-18% -$3.13K ﹤0.01% 8136
2022
Q3 		$15K Buy
1,534
+62
+4% +$626 ﹤0.01% 7821
2022
Q2 		$13K Buy
1,472
+210
+17% +$1.72K ﹤0.01% 7536
2022
Q1 		$11K Sell
1,262
-66
-5% -$585 ﹤0.01% 8313
2021
Q4 		$12K Buy
1,328
+1,214
+1,065% +$10.8K ﹤0.01% 8570
2021
Q3 		$1K Sell
114
-1,205
-91% -$12.8K ﹤0.01% 9221
2021
Q2 		$15K Sell
1,319
-1,189
-47% -$14.8K ﹤0.01% 7645
2021
Q1 		$32K Buy
2,508
+1,592
+174% +$22.2K ﹤0.01% 6959
2020
Q4 		$14K Buy
+916
New +$14K ﹤0.01% 7220

Other funds holding PHAR

MACM
MAC Alpha Capital Management Tampa, Florida $216M AUM
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
SGFG
Silver Grove Financial Group Orchard Park, New York $185M AUM 28.01% 1-Year Est. Return
NSG
Nalls Sherbakoff Group Knoxville, Tennessee $141M AUM 25.05% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM

UBS Group's PHAR Position: Q2 2026 in Review

UBS Group opened a new position in Pharming Group (PHAR) in Q2 2026: 39 shares worth $542. The stake represents ﹤0.01% of the portfolio and ranks #9807 among its holdings. This is a return to the name: UBS Group previously reported a position in PHAR as recently as Q4 2025.

UBS Group first reported a position in PHAR in Q4 2020 and has held it in 15 quarters since. The position peaked at $32K in Q1 2021. 17 funds tracked by Wall St. Rank hold PHAR as of Q2 2026.

  • UBS Group held 39 shares of Pharming Group worth $542 as of Q2 2026.
  • Pharming Group was a new UBS Group position in Q2 2026.
  • Pharming Group made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9807 holding.
  • UBS Group first reported a position in Pharming Group in Q4 2020 and has held it in 15 quarters since.
  • UBS Group's Pharming Group position peaked at $32K in Q1 2021.
  • 17 funds tracked by Wall St. Rank held Pharming Group as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.